By the Numbers
U.S. Pharm.D. Program
U.S. News World & Report
Among Schools of Pharmacy in NIH and Total Research Funding
University World-Wide in Pharmacology, Toxicology U.S. News World & Report
Best in Pharmacy and Pharmaceutical Sciences
2020 ShanghaiRanking Global Rankings
Our Research Enterprise
We are organized based on the drug development, delivery and patient care cycle.
Find and characterize new therapeutic targets and agents
Deliver therapeutic agents for successful outcomes
Discover and evaluate the factors that influence how therapeutic agents work
Identify the health outcomes and value of therapies, policies and practices
Advance education and the practice of pharmacy
A Culture of Collaboration
Partnering across the campus, state, nation and around the world to advance research, education and practice.
UNC Health Sciences Campus
The School is part of the University of North Carolina at Chapel Hill, a major research university with a large teaching hospital and schools of medicine, public health, nursing, and dentistry.
- Ranked 5th nationally for federal research among all universities
- $1.1 billion in sponsored research from all sources annually
- Eleventh largest research university in research volume and annual expenditures
Eshelman Institute for Innovation
The Eshelman Institute for Innovation was established in 2014 with a $100 million commitment from Dr. Fred Eshelman. The Institute encourages collaborations between universities, research institutions, foundations and industry that accelerate groundbreaking science from the bench to the patient by funding and translating ‘top tier’ scientific solutions to the market with speed. Learn more here.
Partnership in Patient Care
The Partnership in Patient Care combines the resources of the School and the UNC Medical Center pharmacy department to increase the pharmacy services available to patients at UNC Hospitals, the amount of experiential education that pharmacy students receive at the UNC Eshelman School of Pharmacy and the amount of point-of-care research being conducted.
Research Triangle Park
UNC anchors one corner of North Carolina’s famed Research Triangle Park, which hosts an abundance of pharmaceutical, biotech, and health-care companies. This environment offers many opportunities for collaboration in research, education, and patient care with partners in academia, industry, and health care.
The University of North Carolina at Chapel Hill and Deerfield Management have entered into a partnership to create Pinnacle Hill, a company seeking to discover new medicines to address the significant unmet medical needs of our times. Deerfield will invest up to $65 million of targeted funding through Pinnacle Hill, as well as providing significant drug development expertise to advance promising therapeutic research at UNC-Chapel Hill. Learn more here.
PharmAlliance is a unique international partnership between three global leaders in pharmacy education, the University of North Carolina at Chapel Hill, Monash University, and University College London. PharmAlliance partners work collaboratively to inspire and train tomorrow’s professional leaders and practitioners to transform education delivery and address major research challenges in pharmacy and the pharmaceutical sciences.
Structural Genomics Consortium
The SGC (Structural Genomics Consortium) is a not-for-profit, public-private partnership that performs basic science of relevance to drug discovery. Research is conducted at several sites around the world to produce reagents, proteins, antibodies, assays, and data that support exploration of the human genome. All material and intellectual output of the SGC is placed in the public domain for use without restriction. The first SGC laboratory to operate in the USA is located in the UNC Eshelman School of Pharmacy. Learn more here.
Rapidly Emerging Antiviral Drug Discovery Initiative (READDI) is a partnership between the Structural Genomics Consortium (SGC), the University of North Carolina at Chapel Hill and the Eshelman Institute for Innovation aimed at discovering and developing drugs to put “on the shelf” for clinical trial testing in anticipation of future viral pandemics.